Fore Therapeutics

Fore Therapeutics is a clinical-stage precision oncology company dedicated to developing innovative therapies for patients with unaddressed genetic cancer drivers. The company utilizes its proprietary Foresight functional genomics platform to characterize a vast library of unclassified mutations and identify those that can be effectively targeted. Its lead asset, plixorafenib (FORE8394), is a potent and selective BRAF inhibitor that targets Class I, II, and III BRAF mutations while uniquely avoiding paradoxical activation of the MAPK pathway. Fore Therapeutics is currently advancing plixorafenib through Phase 2 clinical trials for patients with BRAF-mutated solid tumors, including primary central nervous system cancers.